Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam
TANG Ke-jing,LUO Yi-feng,SU Xia,HE Bei,SHI Guo-chao,SONG Li-qiang,WEN Fu-qiang,LYU Xiao-ju,CHEN Bai-yi,XIONG Sheng-dao,ZHAO Jian-ping,ZHANG Tian-tuo,ZHOU Jian-ying,YU Yun-song,CAO Bin,XIAO Wei,PAN Pin-hua,SHI Yi,LIN Qi-chang,CHEN Yi-qiang,NI Yu-xing,XIE Can-mao
DOI: https://doi.org/10.11816/cn.ni.2017-171263
2017-01-01
Abstract:OBJECTIVE To evaluate the efficacy and economy of cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam in treatment of gram-negative bacteria infections.METHODS By means of non-random observational study, the data of antibiotics therapy were collected from 322 patients with gram-negative bacteria infections who were hospitalized from Jan 1, 2012 to May 11, 2016 and were treated with cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam.The pharmacoeconomics were evaluated with the use of cost-effectiveness analysis method.RESULTS The data were obtained from a large sample, non-random, and active surveillance study, the between-group covariate imbalance phenomenon existed in the original data, and the between-group covariate imbalance phenomenon was remarkably improved after they were matched by using propensity scoring method.After the matching, the economic analysis of costs of target antibiotics was carried out after the matching.As compared with cefoperazone-sulbactam and imipenem-cilastatin, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 39.15 yuan, 51.02 yuan, 52.61 yuan, and 40.09 yuan, respectively;while the imipenem-cilastatin needed 75.54 yuan, 81.28 yuan, 83.39 yuan, and 72.15 yuan respectively.As compared with cefoperazone-sulbactam and piperacillin-tazobactam, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 36.94 yuan, 46.80 yuan, 48.40 yuan, and 33.42 yuan, respectively;while piperacillin-tazobactam needed 99.99 yuan, 117.64 yuan, 121.21 yuan, and 95.23 yuan, respectively.The four cost-effectiveness analyses showed that cefoperazone-sulbactam had obvious economic advantages.Under the circumstances of the same efficacy, the cost of cefoperazone-sulbactam was 1/3~1/2 of the cost of piperacillin-tazobactam and imipenem-cilastatin.The sensitivity analysis based on the 95% confidence limit of efficacy showed that the conclusion remained true.CONCLUSION Cefoperazone-sulbactam has more cost-effectiveness advantages on treatment of the gram-negative bacteria (including multidrug-resistant organisms) infections.